Trial · NCT06945666
A Study of Iguratimod in Combination With Tofacitinib in RA Patients
NCT06945666, Phase 4, Not yet recruiting, Jie Chang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Iguratimod in Combination With Tofacitinib in RA Patients. Trials, record NCT06945666. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06945666
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Iguratimod in Combination With Tofacitinib in RA Patients
- NCT number
- NCT06945666
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Jie Chang
- Conditions
- Rheumatoid Arthritis (RA
- Interventions
- Combined therapy of Iguratimod and tofacitinib
- First posted
- 2025-04-25
- Last updated
- 2025-04-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ACR20 (%) | 12 and 24 weeks of treatment | American College of Rheumatology 20% improvement criteria (ACR20) response rates(Expressed as a percentage value) at 12 and 24 weeks of treatment. |
| Primary | ACR50 (%) | 12 and 24 weeks of treatment | American College of Rheumatology 50% improvement criteria (ACR50) response rates(Expressed as a percentage value) at 12 and 24 weeks of treatment. |
| Primary | ACR70 (%) | 12 and 24 weeks of treatment | American College of Rheumatology 70% improvement criteria (ACR70) response rates(Expressed as a percentage value) at 12 and 24 weeks of treatment. |
| Primary | DAS28 | 12 and 24 weeks of treatment | Changes in disease activity score (DAS28) from baseline at 12 and 24 weeks of treatment. This score has no unit of measure. |
| Secondary | ESR (mm/h) | 4, 8, 12, and 24 weeks of treatment | Changes in erythrocyte sedimentation rate (ESR, millimeters per hour) from baseline at 4, 8, 12, and 24 weeks of treatment. |
| Secondary | CRP (mg/L) | 4, 8, 12, and 24 weeks of treatment | Changes in C-reactive protein (CRP, milligrams per liter) levels from baseline at 4, 8, 12, and 24 weeks of treatment. |
| Secondary | RF (IU/L) | 4, 8, 12, and 24 weeks of treatment | Changes in rheumatoid factor (RF, international units per liter) levels from baseline at 4, 8, 12, and 24 weeks of treatment. |
| Secondary | CCP (U/L) | 4, 8, 12, and 24 weeks of treatment | Changes in anti-cyclic citrullinated peptide antibody (CCP, units per liter) levels from baseline at 4, 8, 12, and 24 weeks of treatment. |
| Secondary | AE | From baseline to 24 weeks of treatment | Incidence of adverse events (AE) of different severity |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06945666
GET https://conductscience.org/api/trials/v1/NCT06945666/registered